Shares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) fell 2.7% during mid-day trading on Friday . The company traded as low as $19.87 and last traded at $20.23. 43,704 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 295,765 shares. The stock had previously closed at $20.80.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on NAMS shares. Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC restated a "buy" rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, November 21st. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma has an average rating of "Buy" and a consensus price target of $33.80.
Read Our Latest Stock Report on NAMS
NewAmsterdam Pharma Trading Down 5.8 %
The firm's 50-day moving average price is $19.37 and its two-hundred day moving average price is $18.58.
Insider Transactions at NewAmsterdam Pharma
In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the transaction, the insider now owns 11,778,760 shares in the company, valued at approximately $295,411,300.80. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 86,803 shares of company stock valued at $1,755,307. 19.50% of the stock is owned by insiders.
Institutional Trading of NewAmsterdam Pharma
Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC acquired a new stake in NewAmsterdam Pharma during the 1st quarter worth $15,018,000. Rosalind Advisors Inc. acquired a new position in shares of NewAmsterdam Pharma in the 2nd quarter valued at approximately $194,000. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Wolverine Asset Management LLC lifted its stake in NewAmsterdam Pharma by 117.7% in the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock valued at $298,000 after buying an additional 8,394 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in NewAmsterdam Pharma by 49.1% in the second quarter. Sei Investments Co. now owns 24,561 shares of the company's stock valued at $472,000 after buying an additional 8,087 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
